Synthesis of new hypoxia markers EF1 and [18F]-EF1.

We report on the preparation of a hypoxia marker 2-(2-nitroimidazol-1[H]-yl)-N-(3-fluoropropyl)acetamide (EF1) and its 18F analog, 2-(2-nitroimidazol-1[H]-yl)-N- (3-[18F]fluoropropyl)acetamide ([18F]-EF1). Two methods for the preparation of 3-fluoropropylamine, the EF1 side chain, are described. [18F]-EF1 was prepared with a radiochemical yield of 2% by nucleophilic substitution of bromine in 2-(2-nitroimidazol-1[H]-yl)-N-(3-bromopropyl)acetamide (EBr1) by carrier-added 18F in DMSO at 120 degrees C. Our results demonstrate the preparation of clinically relevant amounts of [18F]-EF1 for use as a non-invasive hypoxia marker with detection using positron emission tomography (PET).

[1]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  D. Podoloff,et al.  Development of new markers for hypoxic cells: [131I]Iodomisonidazole and [131I]Iodoerythronitroimidazole. , 1996, Journal of drug targeting.

[3]  T. Tewson.  Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia. , 1997, Nuclear medicine and biology.

[4]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  G. Johnson,et al.  99mTc-HL91. Effects of low flow and hypoxia on a new ischemia-avid myocardial imaging agent. , 1997, Circulation.

[6]  J. Rasey,et al.  Positron emission tomography. A new tool for characterization of malignant disease and selection of therapy. , 1994, Acta oncologica.

[7]  M J Welch,et al.  Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[8]  P Vaupel,et al.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  G. Krejcarek,et al.  Covalent attachment of chelating groups to macromolecules. , 1977, Biochemical and biophysical research communications.

[10]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[11]  L. Golberg,et al.  Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. , 1992, British Journal of Cancer.

[12]  K. Krohn,et al.  Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. , 1987, Radiation research.

[13]  J. D. Chapman,et al.  Radioiodinated 1-(2-fluoro-4-iodo-2,4-dideoxy-beta-L-xylopyranosyl)-2-nitroimidazole: a novel probe for the noninvasive assessment of tumor hypoxia. , 1992, Radiation research.

[14]  A. J. Varghese,et al.  Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. , 1976, Cancer research.

[15]  M J Welch,et al.  Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia. , 1987, Life sciences.

[16]  M. Parliament,et al.  Imaging tumor hypoxia and tumor perfusion. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  C. Koch,et al.  Metabolism induced binding of 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration. , 1984, International journal of radiation oncology, biology, physics.

[18]  C. Koch,et al.  Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. , 1995, British Journal of Cancer.

[19]  L. Harwell,et al.  Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. , 1993, Cancer research.

[20]  C. Mathis,et al.  A radiosynthesis of fluorine-18 fluoromisonidazole. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  A. Nunn,et al.  TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. , 1994, Journal of medicinal chemistry.

[22]  C. Koch,et al.  Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.

[23]  L. Wiebe,et al.  Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues. , 1996, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[24]  S. Barrington,et al.  Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[26]  R. Bradshaw,et al.  The Gabriel Synthesis of Primary Amines , 1968 .

[27]  David J. Yang,et al.  Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. , 1995, Radiology.

[28]  Jean Charles Gilbert,et al.  Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  J. D. Chapman,et al.  Synthesis and in vivo studies of the radiosensitizer 4-[82Br]bromomisonidazole. , 1983, International journal of nuclear medicine and biology.